FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Biocartis announced that bioMérieux and Biocartis have signed an agreement to end their alliance for the development and commercialization of the integrated molecular biology system, IdyllaTM (previously Apollo), in the field of microbiology molecular diagnostics. bioMérieux will return all rights on the IdyllaTM platform to Biocartis. read more
Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate an exploratory Phase 2 study with GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis, a third indication for this investigational molecule, in addition to psoriasis and lupus. read more
TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings. read more
Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 165,000 common shares have been issued by the Company in exchange for 330,000 Euro as the result of the exercise of warrants by some employees and consultants of the Company. read more
BONE THERAPEUTICS, the regenerative therapy company addressing unmet needs in the field of orthopaedics via a minimally invasive approach, today announces it has received clearance from the Competent Authorities in Belgium, France and the Netherlands to initiate a phase IIb/III trial with its autologous cell therapy product, PREOB®, for the treatment of non-union fractures. First patients have already been treated in Belgium. read more
Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it is part of a consortium which has been awarded a highly competitive European Union Seventh Framework Programme for Research and Innovation (FP7) research grant from the European Union to support the development of a bioresorbable polymeric valve tube for the treatment of patient suffering congenital heart defects. read more
Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP (BVF Partners LP), Biotech Value Fund Inc (BVF Inc) and Sofinnova Partners SAS. read more
TiGenix NV (Euronext Brussels: TIG) announced today the successful completion of the EUR 12 million capital increaseannounced on November 20, 2013. In total, 34.188.034 new ordinary shares were issued to Gri-Cel S.A., a fully-owned subsidiary of global healthcare company Grifols S.A. TiGenix will prepare and, after approval by the FSMA, publish a prospectus regarding the admittance of the new shares to trading on NYSE Euronext Brussels, which is expected to take place in the following weeks. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its Founder and Chairman Prof Desire Collen has received the Scrip Lifetime Achievement award. He was presented with this prestigious industry award at the Scrip Awards 2013 event held in London last night. read more
The Belgian biotechnology company Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris : CARD), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, is pleased to announce that it has won the Trends-Tendances Business Tour 2013 Award in the “Innovation” category for Wallonia. read more